FFT, Inflammation, Lipid Metabolism, Blood Pressure and Organ Damage in Patients With Obesity, Chronic Kidney Disease (CKD).
FFT, Inflammation, Lipid Metabolism, Blood Pressure and Organ Damage in Patients With Obesity, Chronic Kidney Disease (CKD).
Fructose intake from added sugars has increased dramatically over the last century and has
 recently been implicated as potential contributor to metabolic syndrome, obesity,
 hypertension, inflammation and kidney disease. Fructose differs from the other sugars
 because, uric acid is generated during its metabolism. Serum uric acid levels have been found
 to correlate with the intake of fructose and added sugars. In turn, an elevated serum uric
 acid has also been shown to be associated with increased risk for cardiovascular and
 metabolic diseases. On the other hand complexity of fructose metabolism in each individuals
 results of the various magnitude of hyperuricemia induced by fructose intake. The magnitude
 of uric acid production in each patient may reflect individual predisposition to endogenous
 urate production in a face of relatively normal fasting uric acid concentration. Therefore
 the oral fructose tolerance test might reveal an occult purine disturbances which plays
 casual role in either metabolic disturbances or organ damage.

 The aim of this study is to see whether is a relationship between fructose induced
 hyperuricemia and metabolic disturbances , inflammatory state and organ damage in obese and
 various stages CKD patients.
The study will be performed in two experimental groups. Proposed study groups Study I
 Patients with BMI> 30 and metabolic syndrome. Patient with BMI> 30 without metabolic
 syndrome. Normal healthy controls. Study II Patients with CKD stage III and uric acid < 7
 mg/dl Patients with CKD stage III and uric acid > 7 mg/dl Patient with asymptomatic
 hyperuricemia and eGFR > 90 ml/min/1.73 m2, , uric acid > 7 mg/dl Hemodialysis patients

 Characteristics of the particular patients group- including criteria:

 10- 15 participants in each subset of each group age 18-65 y. Gender: females and males in
 equal proportion. Group I Patients with BMI> 30 and metabolic syndrome ( ATP III). Patient
 with BMI> 30 without metabolic syndrome. Normal healthy control- healthy persons( without
 renal disease, cardiovascular diseases, diabetes mellitus, BMI < 25;normotensives ).

 Group II Patients with CKD stage III (GFR 30-59 ml/min/1,73 m2) and uric acid < 7 mg/dl.

 -  without diabetes mellitus proteinuria < 3,5 g/24 h without immunosuppressive agents,
 ACEi, ARB, allopurinol treatment well controlled hypertension ( < 140/90 mmHg) Patients
 with CKD stage III(GFR 30-59 ml/min/1,73 m2) and uric acid > 7 mg/dl

 -  without diabetes mellitus proteinuria < 3,5 g/24 h without immunosuppressive agents,
 ACEi, ARB, allopurinol treatment well controlled hypertension ( < 140/90 mmHg)

 Patient with asymptomatic hyperuricemia, uric acid > 7 mg/dl with normal renal function
 Hemodialysis patients.

 -  CKD: nondiabetic nephropathy

 -  duration hemodialysis 3-48 months

 -  Hb-11-13 g/dl

 -  well controlled hypertension ( < 140/90 mmHg)

 -  without ACEi, ARB, allopurinol treatment

 -  residual diuresis will be estimated for last 48 hours-between mid and next dialysis
 Method of investigation All patients and controls ( but hemodialysis) will present after
 overnight fast. Baseline tests include 24 hr urine collection for: sodium, calcium,
 phosphorus, creatinine, uric acid, NAG, albumin will be carry out and the same morning
 fasting sample of blood for: creatinine, cystatin C , uric acid, sodium, glucose,
 insulin, triglycerides, HDL and LDL cholesterol, calcium, phosphorus, hsCRP. BP will be
 determined as the mean of three readings taken 5 min apart while sitting. Next in all
 patients and controls fructose tolerance test will be performed. The test consists of
 giving 1 gram/kg b.w. of fructose p.o. with blood collection at 0,30,60 and 120 min
 afterward for serum uric acid determination and uric acid area under the curve will be
 calculated. The calculated area under curve is the measure of occult uric acid
 disturbance when compared to controls.

 Day before the urine collection the ABPM , BMI, IM (intima media ratio) , renal duplex
 ultrasound (RI) will be done

 Measure BMI, waist circumference
Inclusion Criteria:

 - Group I Patients with BMI> 30 and metabolic syndrome ( ATP III). Patient with BMI> 30
 without metabolic syndrome. Normal healthy control- healthy persons( without renal disease,
 cardiovascular diseases, diabetes mellitus, BMI < 25;normotensives ).

 Group II Patients with CKD stage III (GFR 30-59 ml/min/1,73 m2) and uric acid < 7 mg/dl.

 -  without diabetes mellitus proteinuria < 3,5 g/24 h without immunosuppressives agents,
 ACEi, ARB, allopurinol treatment well controlled hypertension ( < 140/90 mmHg)
 Patients with CKD stage III(GFR 30-59 ml/min/1,73 m2) and uric acid > 7 mg/dl

 -  without diabetes mellitus proteinuria < 3,5 g/24 h without immunosuppressive agents,
 ACEi, ARB, allopurinol treatment well controlled hypertension ( < 140/90 mmHg)

 Patient with asymptomatic hyperuricemia, uric acid > 7 mg/dl with normal renal function
 Hemodialysis patients.

 -  CKD: nondiabetic nephropathy

 -  duration hemodialysis 3-48 months

 -  Hb-11-13 g/dl

 -  well controlled hypertension ( < 140/90 mmHg)

 -  without ACEi, ARB, allopurinol treatment

 -  residual diuresis will be estimated for last 48 hours-between mid and next dialysis

 Exclusion Criteria:

 -  immunosuppressive agents, ACEi, ARB, allopurinol treatment

 -  diabetes mellitus

 -  not well controlled hypertension ( > 140/90 mmHg)

 -  proteinuria > 3,5 g/24 h